{
    "clinical_study": {
        "@rank": "107625", 
        "arm_group": {
            "arm_group_label": "Aloglipin", 
            "description": "Aloglipin 25 mg, tablets, orally, once daily for up to 12 months"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the safety and efficacy of long-term treatment with\n      alogliptin (Nesina) in patients with mild type 2 diabetes mellitus in the routine clinical\n      setting."
        }, 
        "brief_title": "Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Surveillance", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance on long-term use of alogliptin, designed to\n      investigate the safety and efficacy of treatment with alogliptin  in patients with mild type\n      2 diabetes mellitus in the routine clinical setting.\n\n      Participants will be patients with mild type 2 diabetes mellitus. The planned sample size is\n      20,000.\n\n      The usual adult dosage for oral use is 1 alogliptin tablet (25 mg of alogliptin) once daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with HbA1c (JDS value) \u22647.0% at the time of enrolment (within 3 months\n             before initiation of Nesina therapy), regardless of the use of antidiabetic\n             medication.\n\n        Exclusion Criteria:\n\n          -  Patients contraindicated for Nesina\n\n               1. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes\n                  mellitus.\n\n               2. Patients with severe infection, pre- or post-operative patients, or patients\n                  with serious traumatic injury.\n\n               3. Patients with a history of hypersensitivity to any ingredient of Nesina."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with mild type 2 diabetes mellitus who have been examined at a medical\n        institution"
            }
        }, 
        "enrollment": {
            "#text": "20000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964963", 
            "org_study_id": "121-015", 
            "secondary_id": "JapicCTI-132283"
        }, 
        "intervention": {
            "arm_group_label": "Aloglipin", 
            "description": "Alogliptin tablets", 
            "intervention_name": "Alogliptin", 
            "intervention_type": "Drug", 
            "other_name": [
                "Nesina", 
                "SYR-322"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Alogliptin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Nesina Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The frequency of adverse events by type, seriousness, time to onset, etc. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.", 
                "measure": "Frequency of Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at month 36 relative to baseline.", 
                "measure": "Change from Baselin in Glycosylated Hemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and  month 36"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964963"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change in the value of fasting blood glucose collected at month 36 relative to baseline.", 
            "measure": "Change from Baselin in Fasting blood glucose", 
            "safety_issue": "No", 
            "time_frame": "Baseline and month 36"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}